These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 5386074)
41. [Method of determination of kaolin-erythrophosphatide time and its clinical value]. Smolianitskiĭ AIa; Shumbalina LF; Detinkina GN; Dynkina IM; Torik ZhN Lab Delo; 1982; (4):234-7. PubMed ID: 6177912 [No Abstract] [Full Text] [Related]
42. [Controlled clinical study of large doses of etaphenone in coronary insufficiency]. Del Guerico R Clin Ter; 1975 Aug; 74(4):337-63. PubMed ID: 1227752 [No Abstract] [Full Text] [Related]
43. [Non-fractionated heparin versus low molecular weight heparin in acute coronary syndromes]. González Pacheco H Arch Cardiol Mex; 2001; 71 Suppl 1():S63-8. PubMed ID: 11565348 [TBL] [Abstract][Full Text] [Related]
44. Intracardiac thrombosis: diagnosis and treatment with case report. Sibinga CT; van de Wall E; Beekhuis H Folia Med Neerl; 1970; 13(5):148-56. PubMed ID: 5491301 [No Abstract] [Full Text] [Related]
45. [Heparin in the pathogenesis, prevention and therapy of ischemic heart disease]. Riecanský I; Kusá O; Luknárová O; Haviar V Vnitr Lek; 1983 May; 29(5):439-45. PubMed ID: 6880060 [No Abstract] [Full Text] [Related]
46. Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit. Steg PG; Juliard JM Eur Heart J; 2004 Oct; 25(19):1667-9. PubMed ID: 15451141 [No Abstract] [Full Text] [Related]
48. [Clinical and electrocardiographic study of myocardiosclerosis after treatment with vitamins B1 and B6]. Rossi C; Vergallo L Minerva Cardioangiol; 1969 Oct; 17(10):768-72. PubMed ID: 5404968 [No Abstract] [Full Text] [Related]
52. [Glyo-syz in the treatment of chronic coronary insufficiency]. Miasnikov LA; Metelitsa VI; Dubinina LT Ter Arkh; 1971 Jul; 43(7):60-2. PubMed ID: 5149763 [No Abstract] [Full Text] [Related]
53. [Sublingual application of heparin L for the treatment of patients with coronary insufficiency]. Korochkin IM Kardiologiia; 1968 Jul; 8(7):50-3. PubMed ID: 4177106 [No Abstract] [Full Text] [Related]
54. [Effects of essential phospholipids in the control and prevention of hyperlipemia in young and middle-aged persons]. Stanković D; Zulić I; Grujić-Vasić J; Nikolin B; Stanković J Med Arh; 1974; 28(3):287-96. PubMed ID: 4469566 [No Abstract] [Full Text] [Related]
55. [Effect of heparin on the physical loading tolerance of chronic coronary insufficiency patients]. Kucheriavyĭ PG; Terno VS; Taktuk EE Vrach Delo; 1981 Sep; (9):39-41. PubMed ID: 7303609 [No Abstract] [Full Text] [Related]
56. [Medical treatment of the intermediate coronary syndrome with heparin]. Ruggiero HA; Previde O; Califano JE; Bare G; Luzzi R; Beilis P Rev Clin Esp; 1978 Oct; 151(1):19-22. PubMed ID: 740966 [No Abstract] [Full Text] [Related]
57. [Effectiveness of small doses of heparin in ischemic heart disease]. Doroshenko GL Vrach Delo; 1973 Nov; 11():27-30. PubMed ID: 4786926 [No Abstract] [Full Text] [Related]
58. Heparin in coronary artery disease: new uses for an old drug. Violaris AG; Angelini GD Br J Hosp Med; 1993 Jan 6-19; 49(1):37-9, 42-3. PubMed ID: 8347182 [TBL] [Abstract][Full Text] [Related]
59. [Prolonged treatment of coronary insufficiency with heparin in clarifying doses and essential phospholipids]. Caruzzo C Therapeutique; 1969 Apr; 45(4):413-9. PubMed ID: 5386074 [No Abstract] [Full Text] [Related]